Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Sýn Q2 2025: slight revenue increase, continued loss and ongoing cost cuts

Sýn reported a slight revenue increase in Q2 2025 to 5,357 million kr. and a net loss of 174 million kr., with an improved first-half cash flow thanks to reduced investments. The company is cutting costs, reducing headcount and pursuing strategic measures such as the joint venture "Sendafélagið" with Nova, which is expected to deliver annual savings and balance sheet relief. For 2025 Sýn forecasts an EBITDAAL of 4.0–4.2 billion kr. and stresses that the measures are intended to support a long-term return to profitability. » Mere på de.investing.com
Nova Limited beats Q2 forecasts, stock rises in premarket

Nova Limited reported non-GAAP EPS of $2.20 for Q2 2025 (forecast $2.10) and record revenue of $220 million, both above expectations, after which the stock rose 4.89% in premarket trading. The company posted 40% year-over-year revenue growth, strong margins, and issued Q3 2025 guidance of $215–227 million in revenue and non-GAAP EPS of $2.20–2.22. CEO Gabby Weissman cited AI as a growth driver and emphasized the importance of the Gate-All-Around strategy; risks remain in supply chains, market saturation, and geopolitical tensions. » Mere på de.investing.com
Vigil Labs raises $5.7 million to build AI-powered 'bionic' traders

Vigil Labs, founded by Kole Lee, raised $5.7 million in a seed round led by Nova to develop a proprietary AI reasoning system and real‑time data infrastructure to augment human traders. The Palo Alto startup combines social, predictive market and traditional data to create a continuous prediction engine and aims to scale into a large AI-driven hedge fund. Founders and early team members include Kole Lee, CTO Calder White and CPO Daniel Nunes; investors include Lux Capital, Pantera Capital and prominent angel backers. » Mere på forbes.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2020 har NOVA EYE MEDICAL LTD allerede udloddet 0,08 € i udbytte. Den seneste udlodning fandt sted i juli 2020.

Virksomhedstal

I det seneste kvartal havde NOVA EYE MEDICAL LTD en omsætning på 10,98 mio. € og et nettoresultat på -585,43 t €

(EUR)	juni 2026	YoY
Omsætning	10,98 mio.	-
Bruttofortjeneste	8,04 mio.	-
Nettoresultat	-585,43 t	-
EBITDA	93,74 t	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	3,58 mio. €
Antal aktier	284,87 mio.
Højeste/laveste i 52 uger	0,0878 € - 0,00167 €
Udbytte	Nej
Beta	0,93
P/E (PE Ratio)	-8,88
PEG (PEG Ratio)	-0,10
K/I (PB Ratio)	2,69
P/S (PS Ratio)	1,10

Virksomhedsprofil

Nova Eye Medical Limited entwirft, entwickelt, vertreibt, vermarktet, verkauft und wartet medizinische Geräte zur Behandlung von Augenkrankheiten. Das Unternehmen bietet iTrack an, ein chirurgisches System zur Senkung des Augeninnendrucks (IOD) bei erwachsenen Patienten mit leichtem bis mittelschwerem Offenwinkelglaukom; Molteno3, ein Glaukom-Drainagegerät zur Behandlung von Patienten mit schwerem oder komplexem Glaukom; und 2RT, eine proprietäre Lasertechnologie zur Behandlung von Patienten mit früher/mittlerer altersbedingter Makuladegeneration. Das Unternehmen ist in Australien, den Vereinigten Staaten, Europa, dem Nahen Osten, Japan, Asien, Südamerika und international tätig. Das Unternehmen war früher unter dem Namen Ellex Medical Lasers Limited bekannt und änderte im Juli 2020 seinen Namen in Nova Eye Medical Limited. Nova Eye Medical Limited wurde 1985 gegründet und hat seinen Hauptsitz in Kent Town, Australien.